[{"data":1,"prerenderedAt":167},["ShallowReactive",2],{"drug-liraglutide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":34,"contraindications":64,"warnings":74,"renal":82,"monitoring":83,"interactions":84,"review":85,"examples":88,"atc":95,"iran":97,"links":109,"populations":127,"usApproval":162},"liraglutide",1,{"fa":7,"en":8},"لیراگلوتاید","Liraglutide","alimentary-metabolism",{"fa":11,"en":12},"آگونیست گیرنده GLP-1","GLP-1 receptor agonist",[14],{"name":15,"market":16},"Victoza","US",[18,19,7],"victoza","ویکتوزا",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":29,"refs":30},"pen-6","injection","sc","6 mg\u002FmL pen (18 mg\u002F3 mL; doses 0.6, 1.2, 1.8 mg)",{"amount":27,"unit":28,"perVolumeMl":5},6,"mg",[16],[31],{"source":32,"section":33},"fda-victoza","3",[35],{"id":36,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":52,"notes":55},"t2d","type-2-diabetes",{"fa":39,"en":40},"دیابت نوع ۲ (۱۰ سال به بالا) — ۰٫۶ mg روزانه، سپس ۱٫۲ و تا ۱٫۸ mg","Type 2 diabetes (≥10 y) — 0.6 mg daily, then 1.2 up to 1.8 mg",{"minAge":42},{"value":43,"unit":44},10,"year","titration",{"dividedDoses":5,"titration":47},{"start":48,"increment":48,"incrementEveryDays":49,"targetMin":50,"targetMax":51,"max":51},0.6,7,1.2,1.8,[53],{"source":32,"section":54},"2.1",[56],{"text":57,"refs":60},{"fa":58,"en":59},"۰٫۶ mg فقط برای تحمل گوارشی است. اگر بیش از ۳ روز قطع شد، از ۰٫۶ mg دوباره شروع.","0.6 mg is only for GI tolerability. If more than 3 days missed, restart at 0.6 mg.",[61,62],{"source":32,"section":54},{"source":32,"section":63},"2.2",[65],{"id":66,"severity":67,"text":68,"refs":71},"mtc","block",{"fa":69,"en":70},"سابقه شخصی یا خانوادگی کارسینوم مدولاری تیروئید یا MEN 2؛ حساسیت جدی.","Personal or family history of medullary thyroid carcinoma or MEN 2; serious hypersensitivity.",[72],{"source":32,"section":73},"4",[75],{"text":76,"refs":79},{"fa":77,"en":78},"هشدار جعبه‌ای: تومور سلول C تیروئید در جوندگان؛ در سابقه MTC یا MEN 2 ممنوع.","Boxed warning: thyroid C-cell tumours in rodents; contraindicated with MTC or MEN 2 history.",[80],{"source":32,"section":81},"Boxed Warning",[],[],[],{"status":86,"reviewer":87,"date":87},"unverified",null,[89],{"regimen":36,"formulation":22,"input":90,"expect":93},{"ageYears":91,"weightKg":92},50,90,{"perDose":48,"mlPerDose":94},0.1,[96],"A10BJ02",{"status":98,"forms":99,"refs":104},"registered",[100],{"code":101,"en":102,"fa":103},"22666","LIRAGLUTIDE INJECTION, SOLUTION 6 mg\u002F1mL 3ML PEN (VICTOZA)","قلم تزریقی لیراگلوتاید ۶ میلی‌گرم \u002F ۱ میلی‌لیتر ۳ میلی‌لیتر (ویکتوزا)",[105],{"source":106,"section":107,"url":108},"darooyab-generic","G-4899\u002FLiraglutide","https:\u002F\u002Fwww.darooyab.ir\u002FG-4899\u002FLiraglutide",[110,114,118,122,125],{"kind":111,"url":112,"label":113},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=022341","NDA022341",{"kind":115,"url":116,"label":117},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4","FDA Victoza",{"kind":119,"url":120,"label":121},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa611003.html","Liraglutide Injection",{"kind":123,"url":124,"label":96},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A10BJ02",{"kind":126,"url":108,"label":8},"darooyab",{"pregnancy":128,"lactation":137,"pediatric":145,"geriatric":153},{"level":129,"text":130,"quote":133,"refs":134},"caution",{"fa":131,"en":132},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on animal reproduction studies, there may be risks to the fetus from exposure to VICTOZA during pregnancy.",[135],{"source":32,"section":136},"8.1",{"level":129,"text":138,"quote":141,"refs":142},{"fa":139,"en":140},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of VICTOZA in human milk, the effects on the breastfed infant, or the effects on milk production.",[143],{"source":32,"section":144},"8.2",{"level":129,"text":146,"quote":149,"refs":150},{"fa":147,"en":148},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of VICTOZA as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus have been established in pediatric patients 10 years of age and older.",[151],{"source":32,"section":152},"8.4",{"level":154,"text":155,"quote":158,"refs":159},"ok",{"fa":156,"en":157},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness for VICTOZA have been observed between patients 65 years of age and older and younger patients.",[160],{"source":32,"section":161},"8.5",{"kind":163,"refs":164,"id":113},"NDA",[165],{"source":32,"section":166},"SPL approval \u002F marketing category",1792111459269]